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Abstract
Background: Pilot and feasibility studies (PAFS) often have complex objectives aimed at assessing feasibility of
conducting a larger study. These may not be clear to participants in pilot studies.
Methods: Here, we aimed to assess the transparency of informed consent in PAFS by investigating whether
researchers communicate, through patient information leaflets and consent forms, key features of the studies. We
collected this data from original versions of these documents submitted for ethics approval and the final approved
documents for PAFS submitted to the Hamilton Integrated Research Ethics Board, Canada.
Results: One hundred eighty-four PAFS, submitted for ethics approval from 2004 to 2020, were included, and we
found that of the approved consent documents which were provided to participants, 83.2% (153) stated the terms
“pilot” or “feasibility” in their title, 12% (22) stated the definition of a pilot/feasibility study, 42.4% (78) of the studies
stated their intent to assess feasibility, 19.6% (36) stated the specific feasibility objectives, 1.6% (3) stated the criteria
for success of the pilot study, and 0.5% (1) stated all five of these criteria. After ethics review, a small increase in
transparency occurred, ranging from 1.6 to 2.8% depending on the criteria. By extracting data from the protocols of
the PAFS, we found that 73.9% (136) stated intent to assess feasibility, 71.2% (131) stated specific feasibility
objectives, and 33.7% (62) stated criteria for success of the study to lead to a larger study.
Conclusion: The transparency of informed consent in PAFS is inadequate and needs to be specifically addressed by
research ethics guidelines. Research ethics boards and researchers ought to be made aware and mindful of best
practices of informed consent in the context of PAFS.
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Background
A feasibility study is a preliminary investigation con-
ducted with the purpose of assessing the feasibility of
conducting a future larger study [1]. Pilot studies are a
subset of feasibility studies, in which the intervention
tested in the subsequent larger study is implemented, or
partially implemented, on a smaller scale to assess feasi-
bility [2]. Research guidance and researchers have been
found to use the terms “pilot” and “feasibility” synonym-
ously [3, 4], and because our study concerns all feasibil-
ity studies, we make no distinction between pilot and
feasibility studies (PAFS) in our investigation.
For the purposes of our study, we identified three
main reasons for conducting PAFS, based on the work
of Thabane et al. [5], PAFS seek to answer feasibility
questions related to process, resources, and management
issues [5–7]. Process-related objectives seek to assess
whether steps that need to be taken to ensure the suc-
cess of the main study are feasible [5–7]. This includes
assessing recruitment rates, acceptability of the interven-
tion, loss to follow-up, and data collection tools.
Resource-related objectives seek to assess whether issues
of resources, like time, money, and capacity, could arise
in the larger study [5–7]. Management-related objectives
seek to assess whether issues of human and data man-
agement could arise in the subsequent study, including
identifying challenges related to data storage and trans-
fer [5–7]. Other frameworks for pilot studies include an-
other category of objectives related to scientific aims,
such as assessing efficacy and safety of interventions [5].
We consider these to be proof of concept or exploratory
studies and thereby do not include them in our defin-
ition of PAFS.
However, ethical issues of informed consent in PAFS
remain largely unaddressed, as they are hardly discussed
in the literature surrounding informed consent and
PAFS [5]. Specifically, the obligation of researchers to
communicate the feasibility nature and objectives of
PAFS to participants of these studies, when obtaining
consent, is an important ethical concern that has not yet
been appropriately addressed by research ethics guide-
lines or investigated by researchers.
The objectives of PAFS can be less intuitive, and from
participants’ perspectives, the studies’ objectives may appear
to be the same as large scale trials and studies. Since in-
formed consent in PAFS is not addressed in many popular
research ethics guidelines, [5] there is substantive concern
that informed consent in PAFS lacks transparency [5, 8].
Transparent communication between researchers and par-
ticipants is essential to maintaining the rights of partici-
pants, credibility of researchers, and trust between
researchers and the public. This is specifically relevant to
PAFS, as many of them do not proceed to larger studies. If
this is not communicated to participants, it can result in a
unique form of therepeutic misconception—where the
intended value of the research differs from the participant’s
percieved value [8]. Additionally, if the feasibility nature of
PAFS is not communicated, the quality of consent can be
diminished by therepeutic misestimation—the tendency for
potential participants to overestimate the benefits and
underestimate the risks of participating in a study [8]. This
is especially concerning in PAFS since their clinical benefits
are reaped after completion of the main study, often much
later; or if the pilot does not lead to a larger study there
may be no clinical benefit. Only about 50% of published
pilot studies stated a larger study was needed [9], and be-
tween 5 and 24% of pilot studies have been found to lead to
future studies [3, 10], highlighting the importance of trans-
parency during the informed consent process in PAFS.
Research ethics guidelines discuss informed consent
as being well informed, meaning participants under-
stand the nature, duration, purpose, methods, risks,
discomforts, benefits, sources of funding, institutional
affiliations of researchers, and potential conflicts of
interest associated with the study [11–15]. Partici-
pants should also be informed of alternatives to par-
ticipating in the study and have the opportunity to
ask questions [11–15]. These principles apply to al-
most all studies involving participants, including pilot
studies, with few exceptions, like when a waiver of
consent or deception is required, as approved by a
research ethics board (REB).
However, many research ethics guidelines, including the
Nuremburg Code [11], Declaration of Helsinki [12], the
Belmont Report [13], International Conference on
Harmonization Good Clinical Practice [14], and the Inter-
national Ethical Guidelines for Health-related Research
Involving Humans [15] do not comment on informed
consent in PAFS. The Tri-Council Policy Statement 2
(TCPS2) [16], Canada’s benchmark for the ethical conduct
of research involving humans, is required to be followed
in order to be eligible to receive government funding and
was revised, in 2018, to include informed consent prac-
tices in pilot studies. Thabane et al. [5] have also devel-
oped recommendations for informed consent practices in
pilot studies, but other research ethics guidelines need to
be updated to address informed consent in PAFS, as evi-
dence suggests, the reporting and methods are inad-
equately approached [3, 5, 9, 10].
Currently, it is unclear whether researchers are effect-
ively communicating the feasibility nature of PAFS to
their participants and providing acceptable levels of
transparency in the informed consent process. After
conducting an informal review of the literature for stud-
ies assessing practices of informed consent in PAFS, we
concluded that this issue has not been empirically inves-
tigated in the literature. Since depriving participants of
complete information on the PAFS they participate in
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has ethical implications and practical consequences, it is
imperative that the issues of informed consent in PAFS
are investigated urgently.
We hypothesized that a large number of PAFS
approved for ethics clearance do not have a transparent
informed consent process. This study is the first attempt
to empirically investigate the transparency of informed
consent in PAFS. We hope that by quantifying the sever-
ity of this issue at one center, we can begin to address it
on a broader scale.
Methods
Herein a brief overview of the methods is presented.
Further details can be found in the published protocol
by Khan et al. [17].
Study objectives
Our primary objective was to assess whether PAFS sub-
mitted to the Hamilton integrated Research Ethics Board
(HiREB), Canada, transparently communicate the pur-
pose of the study to participants through their informed
consent practice. The HiREB is McMaster University’s
primary research ethics board. McMaster University is
Canada’s most research-intensive, medical doctoral uni-
versity [18], so the HiREB reviews many clinically ori-
ented studies as well as studies from other departments
at the university—including non-medical studies. For
our purposes, a highly transparent informed consent
practice requires that the informed consent documents,
consisting of consent forms and participant information
leaflets, effectively communicate: (1) the term “pilot” or
“feasibility” in the title of the study; (2) the definition of
a pilot or feasibility study; (3) the objectives or purpose
of the study are stated clearly as assessing feasibility; (4)
the specific feasibility objectives of the study; and (5) the
progression criteria—the criteria for the feasibility study
to successfully lead to the main study.
Our secondary objectives were (1) to assess whether
there was a difference between the originally submitted
informed consent documents and the final informed
consent documents revised by the HiREB (revisions
made in order to obtain research ethics approval), spe-
cifically in addressing the issues and criterion discussed
in the primary objective; (2) to determine methodo-
logical characteristics associated with increased report-
ing or inclusion of the criterion discussed in the primary
objectives within the original and revised informed con-
sent documents; and (3) to assess the consistency with
which PAFS assess feasibility outcomes as their primary
objectives.
Sample selection and size
All pilot and feasibility studies submitted to the HiREB,
from January 2004 to December 2020, inclusive, that
used the terms “pilot” or “feasibility” in their title and
obtained participant consent were included in our study.
All pilot and feasibility studies that had a waiver of con-
sent were excluded.
To determine the sample size, we used the estimation
method for a single proportion [17, 19]. The statistical
formula behind the method uses an estimation for a sin-
gle proportion—the proportion can be from a variable
tested in the study and calculates the sample size needed
for a given margin of error of the estimate and confi-
dence interval (CI). In this method, an estimated propor-
tion of 50% yields the largest necessary sample size.
Thus, if the true proportion of pilot studies that use the
term “pilot” or “feasibility” in the title of the study, as
stated on the consent form, is 0.5, which will be esti-
mated with a 95% CI and margin of error 0.40 to 0.60,
then a sample size of 96 would be sufficient to address
our objectives. We decided that if more than 96 studies
met the inclusion criteria, we would include all of them
in our study up to a maximum of 500, to decrease the
width of the CI.
Data collection
Anonymized data was extracted from the online HiREB
database, with a subset of data (about 15%) extracted in
duplicate. All disagreements in data collection were re-
solved by a third party, with a Kappa value and 95% CI
calculated to assess agreement. Specific information col-
lected from originally submitted and revised informed
consent documents to address the primary objective and
to compare transparency of original and revised docu-
ments included (1) if the term “pilot” or “feasibility” was
in the title of the consent documents; (2) if a definition
of pilot or feasibility study was stated; (3) if the objec-
tives or purpose of the study was stated as to assess
feasibility; (4) if the specific feasibility objectives of the
study were stated; and (5) whether the progression cri-
teria was stated.
Data extracted from the study protocols to address the
secondary objectives included the following: use of
randomization; whether the study was observational or
interventional; whether data collected was quantitative,
qualitative, or both; desired sample size; year of submis-
sion for ethics review; sources of funding; whether the
study was approved by the REB; whether the study was
labelled a “pilot” or “feasibility” study; whether intent to
assess feasibility was stated; whether specific feasibility
objectives were stated; whether progression criteria were
stated; and the specific feasibility objectives of the
studies.
Data analysis
Data addressing the primary objective was used to calcu-
late proportions of studies in the sample, with their
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corresponding 95% CI, that reported each item (from
the primary objective), all five items, and at least one of
the five items before and after HiREB review. Descriptive
statistics were used to summarize characteristics of the
studies. An exploratory analysis using multivariable bin-
ary logistic regression was used to determine character-
istics associated with transparent consent practices, with
the criteria from the primary objective used as the
dependent variable and the independent variables being
the study characteristics, including year of submission
(before 2017 or after/during 2017); whether it was titled
a pilot or feasibility study; study design (randomized,
non-randomized with an intervention, or observational);
type of data collected (quantitative, qualitative, or both);
funding (industry sponsored or not), and whether the
protocol stated progression criteria for the study to lead
to a larger study. The Consolidated Standards of Report-
ing Trials (CONSORT) extension [20] for pilot studies
was published in late 2016 and for this reason we cate-
gorized the study dates to before 2017 and after or dur-
ing 2017. Multivariable binary logistic regression results
are reported as odds ratios with 95% CIs used to assess
statistical significance. Analysis was performed using
IBM SPSS Statistics version 26.
Ethics approval
This study was approved by the HiREB (project # 7071-
C), which granted a waiver of consent for the research
team to access the files and consent forms from pilot
and feasibility studies submitted to the HiREB.
Results
Overview of studies
After an initial search of the HiREB databases, 1157
studies were identified as potential PAFS. After remov-
ing duplicates and performing both title and full-text
screenings, 184 studies were deemed eligible and in-
cluded (Fig. 1). The studies included were conducted in
Canada and submitted to the HiREB between 2004 and
March of 2020. Most of the studies included were la-
belled as pilot studies, collected only quantitative data,
were non-industry funded, and were submitted prior to
2017. Detailed descriptions of characteristics of studies
included can be found in Table 1.
Transparency of informed consent documents
Two hundred eighty observations from 30 studies were
recorded in duplicate and a kappa value of 0.79 (95% CI
0.71, 0.83) was calculated for inter-rater reliability. Of
the original informed consent documents submitted for
ethics approval, 80.4% (95% CI 74.7, 86.2) included the
terms “pilot” or “feasibility” in their titles; 9.2% (95% CI
5.1, 13.4) stated the definition of a pilot/feasibility study;
40.8% (95% CI 33.7, 47.9) stated the objectives of the
study related to assessing feasibility; 19.6% (95% CI 13.8,
25.3) stated the specific feasibility objectives of the study;
1.6% (95% CI 0.0, 3.5) stated the progression criteria for
the study (Table 2). Of the original informed consent
Fig. 1 Flow diagram of the study inclusion process
Table 1 characteristics of studies included (n = 184)
Study characteristic n, (%)














2017 to 2020 49 (26.6)
Desired sample size Median (min, max)
50 (5, 1152)
Industry funded 13, (7.1)
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documents submitted for ethics approval, 87.5% (95% CI
82.7, 92.3) of studies included at least one of the five cri-
teria for transparency and only one study stated all five
criteria for transparency (Table 2).
After the informed consent documents were reviewed,
revised, and approved by the HiREB, slight increases in
the inclusion of criteria for transparency of informed
consent occurred. Reporting of the terms “pilot” or
“feasibility” in the titles of informed consent documents,
stating the definition of a pilot/feasibility study, stating
intent to assess feasibility, and studies including at least
one item increased between 1.6 and 2.8% (Table 2).
However, there was no increase in studies describing
their specific feasibility objectives or progression criteria
in their informed consent documents (Fig. 2).
Pilot and feasibility study objectives according to study
protocol
73.9% (95% CI 67.6, 80.3) and 71.2% (95% CI 64.7,
77.7) of PAFS had the aim of assessing feasibility and
stated their specific feasibility objectives, respectively
(Additional file 1: Appendix 1A). However, only about
a third of studies stated their progression criteria
(Additional file 1: Appendix 1A).
We found that 70.7% (95% CI 64.1, 77.2) of studies
assessed process related feasibility objectives; 21.2% (95%
CI 15.3, 27.1) assessed resource-related objectives; and
9.2% (95% CI 5.1, 13.4) assessed management-related
feasibility objectives (Additional file 1: Appendix 1B). If
a study stated any specific feasibility objectives, each
objective was grouped into one of these three categories
(process, resource, or management). Thus, almost a
third of studies stated no specific feasibility objectives at
all (Additional file 1: Appendix 1B).
Characteristics of studies with transparent informed
consent
Of the studies that incorporated the criteria for transpar-
ency in their originally submitted informed consent
documents, most of them were labelled pilot studies,
collected only quantitative data, were non-industry
funded, submitted prior to 2017 and their protocols
stated intent to assess feasibility and specific feasibility
objectives (Additional file 2: Appendix 2). Moreover,
Table 2 Percentage of informed consent forms clearly communicating each of the criteria for transparency before and after
research ethics board review (n = 184)
Item Percentage of originally submitted studies with consent
forms including the criteria (%) (95% confidence interval)
Percent of revised studies with consent forms
including the criteria (%) (95% confidence interval)
“Pilot/feasibility” in
title
80.4 (74.7, 86.2) 83.2 (77.7, 88.6)
Definition of pilot/
feasibility study
9.2 (5.1, 13.4) 12.0 (7.3, 16.6)
Objectives state
assessing feasibility
40.8 (33.7, 47.9) 42.4 (35.3, 49.5)
Specific feasibility
objectives
19.6 (13.8, 25.3) 19.6 (13.8, 25.3)
Progression criteria 1.6 (0.0, 3.5) 1.6 (0.0, 3.5)
All five items
above
0.5 (0.0, 1.6) 0.5 (0.0, 1.6)
At least one item 87.5 (82.7, 92.3) 89.7 (85.3, 94.1)
Fig. 2 Percentage of informed consent forms clearly communicating each of the criteria for transparency before and after research ethics board
review (n = 184). Error bars show 95% confidence intervals
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most of the studies that stated specific feasibility objec-
tives in their informed consent documents were observa-
tional studies. The same trends were found after REB
review (Additional file 2: Appendix 2). The fifth
criteria—whether the studies stated the progression
criteria for the study to lead to a larger study in the
informed consent documents—was not included in the
tables since only three studies reported this item.
Looking at the relative inclusion of the criteria for
transparency between studies of differing characteris-
tics, in the originally submitted informed consent
documents, we found that studies labelled “feasibility”
studies generally had a higher percent inclusion of
the items, thereby greater transparency, compared to
“pilot” studies (Table 3). Randomized studies and ob-
servational studies consistently had a higher percent
inclusion of the criteria for transparency, compared to
non-randomized interventional studies (Table 3).
Studies collecting qualitative data were found to have
lower percent inclusion for each criteria compared to
quantitative studies and studies that collected both
types of data (Table 3). Industry-funded studies had a
lower percent inclusion rate for almost all criteria,
compared to non-industry-funded studies (Table 3).
Studies submitted for review prior to 2017 and after
or during 2017 had comparable percent inclusion for
each criterion (Table 3). Studies that stated intent to
assess feasibility, specific feasibility objectives, and
progression criteria in their protocols had much
higher percent inclusion of the criteria for transpar-
ency compared to studies that did not (Table 3). The
same trends were discovered for studies post REB
review (Table 3).
Table 3 Relative inclusion of criteria for transparency based on each study characteristic for informed consent documents before
and after research ethics board review
Study characteristic Studies that use
the term “pilot”
or “feasibility” in




















Before After Before After Before After Before After
Term used in title of the study
“Pilot” (n = 147) 78.9 82.3 9.5 12.9 32.0 34.0 16.3 16.3
“Feasibility” (n = 32) 87.5 87.5 6.3 6.3 75.0 75.0 28.1 28.1
Both (n = 5) 80.0 80.0 20.0 20.0 80.0 80.0 60.0 60.0
Study design
Randomized (n = 63) 74.6 77.8 15.9 22.2 44.4 47.6 20.6 20.6
Non-randomized interventional (n = 54) 74.1 74.1 0.0 0 31.5 33.3 9.3 9.3
Observational (n = 67) 91.0 95.5 10.4 11.9 44.8 44.8 26.9 26.9
Data collected
Quantitative (n = 121) 80.2 82.6 10.7 14.9 38.8 40.5 19.8 20.7
Qualitative (n = 12) 58.3 58.3 0.0 0 33.3 33.3 16.7 8.3
Both (n = 51) 86.3 90.2 7.8 7.8 47.1 49.0 19.6 19.6
Source of funding
Industry funded (n = 13) 76.9 76.9 0.0 0.0 30.8 30.8 23.1 23.1
Non-industry funded (n = 171) 80.7 83.6 9.9 12.9 41.5 43.3 19.3 19.3
Year of submission
2016 or prior (n = 135) 81.5 83.0 8.9 10.4 40.0 41.5 21.5 21.5
2017 onward (n = 49) 77.6 83.7 10.2 16.3 42.9 44.9 14.3 14.3
Objectives from protocol state intent to assess feasibility (n = 136) 80.1 82.4 11.8 15.4 54.4 56.6 26.5 26.5
Objectives from protocol do not state intent to assess feasibility (n = 48) 81.3 85.4 2.1 2.1 2.1 2.1 0.0 0.0
Specific feasibility objectives stated in protocol (n = 131) 79.4 82.4 11.5 15.3 54.2 56.5 27.5 27.5
No specific feasibility objectives stated in protocol (n = 53) 83.0 84.9 3.8 3.8 7.5 7.5 0.0 0.0
Progression criteria stated in protocol (n = 62) 85.5 87.1 17.7 22.6 53.2 56.5 27.4 27.4
No progression criteria stated in protocol (n = 122) 77.9 81.1 4.9 6.6 34.4 35.2 15.6 15.6
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Results of the exploratory multivariable logistic regres-
sion, adjusting for various study characteristics, showed
that studies that collected qualitative data were much
less likely to include the terms “pilot” or “feasibility” in
the titles of their informed consent documents com-
pared to studies that collected both quantitative and
qualitative data (Table 4). The odds ratio (OR) was 0.19
(95% CI 0.04, 0.82; p = 0.027), for originally submitted
informed consent documents, and 0.13 (95% CI 0.03,
0.61; p = 0.010), for revised informed consent docu-
ments. The OR for all characteristics and their associ-
ation with inclusion of the terms “pilot” or “feasibility”
in the titles of informed consent documents can be
found in Table 4.
Similarly, when adjusting for study characteristics,
studies labelled as “feasibility” studies and studies that
stated progression criteria in their protocol were asso-
ciated with stating feasibility objectives in their
consent documents. “Feasibility” studies were signifi-
cantly more likely than “pilot” studies to state intent
to assess feasibility in their informed consent docu-
ments, with an OR of 8.09 (95% CI 3.11, 21.03; p <
0.001), for originally submitted informed consent doc-
uments, and an OR of 7.44 (95% CI 2.85, 19.41; p <
0.001), for revised informed consent documents (Table
5). Studies that stated the progression criteria in their
protocols were more likely to state intent to assess
feasibility in their informed consent documents, com-
pared to studies that did not, with an OR of 2.37 (95%
CI 1.14, 4.91; p = 0.021), for originally submitted in-
formed consent documents, and an OR of 2.59 (95%
CI 1.25, 5.36; p = 0.011), for revised informed consent
documents (Table 5). The OR for all characteristics
and their associations with stating the objective of
assessing feasibility in the informed consent docu-
ments can be found in Table 5.
Table 4 Study characteristics associated with whether consent documents state “pilot” or “feasibility” in their titles (n = 184)




Odds ratio (95% confidence
interval)
Odds ratio (95% confidence
interval)
2017 or more recent 2016 or prior 0.81 (0.33, 1.99) 1.11 (0.41, 2.98)
Studies labelled as feasibility
studies
Studies labelled as pilot studies 1.72 (0.54, 5.43) 1.31 (0.41, 4.20)
Randomized studies Non-randomized interventional studies 0.73 (0.26, 2.03) 0.64 (0.21, 1.90)
Observational studies Non-randomized interventional studies 1.79 (0.63, 5.15) 1.64 (0.53, 5.12)
Quantitative studies Studies collecting both quantitative and qualitative
data
0.73 (0.26, 2.00) 0.65 (0.21, 2.01)
Qualitative studies Studies collecting both quantitative and qualitative
data
0.19 (0.04, 0.82) 0.13 (0.03, 0.61)
Industry sponsored Non-industry sponsored studies 0.73 (0.17, 3.18) 0.66 (0.15, 2.89)
Progression criteria stated in
protocol
No progression criteria stated in protocol 1.74 (0.71, 4.28) 1.53 (0.59, 3.96)
Table 5 Study characteristics associated with whether consent documents state intent to assess feasibility (n = 184)




Odds ratio (95% confidence
interval)
Odds ratio (95% confidence
interval)
2017 or more recent 2016 or prior 0.84 (0.38, 1.87) 0.80 (0.36, 1.78)
Studies labelled as feasibility
studies
Studies labelled as pilot studies 8.09 (3.11, 21.03) 7.44 (2.85, 19.41)
Randomized studies Non-randomized interventional studies 2.34 (0.91, 6.03) 2.49 (0.97, 6.35)
Observational studies Non-randomized interventional studies 2.02 (0.84, 4.85) 1.83 (0.77, 4.35)
Quantitative studies Studies collecting both quantitative and qualitative
data
0.49 (0.22, 1.09) 0.47 (0.21, 1.04)
Qualitative studies Studies collecting both quantitative and qualitative
data
0.66 (0.16, 2.76) 0.63 (0.15, 2.61)
Industry sponsored Non-industry sponsored studies 0.38 (0.09, 1.65) 0.34 (0.08, 1.46)
Progression criteria stated in
protocol
No progression criteria stated in protocol 2.37 (1.14, 4.91) 2.59 (1.25, 5.36)
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Discussion
This is the first study, to our knowledge, looking at
transparency of informed consent in PAFS. We found
that whilst most studies reported the term “pilot” or
“feasibility” in the title, less than half stated intent to as-
sess feasibility in the informed consent documentation,
and few included a definition of a pilot or feasibility
study, the specific feasibility objectives, and the progres-
sion criteria in the informed consent documents. Only
one study was found to include all five criteria. These re-
sults support our hypothesis that the transparency of in-
formed consent in PAFS is, in many cases, inadequate.
Our secondary objectives included assessing whether
there is a difference between the originally submitted
and revised versions of the informed consent documents,
with revisions suggested and made to obtain ethics ap-
proval, specifically in addressing the issues and criterion
discussed in the primary objective. We found that after
REB review, the proportion of studies stating “pilot” or
“feasibility” in the title, the definition of a pilot or feasi-
bility study, or the objectives to assess feasibility in the
informed consent documents increased between 1.6%
and 2.8%. There was no change in studies stating the
specific feasibility objectives or progression criteria. This
suggests that there is little improvement in transparency
of informed consent in PAFS as a result of the REB re-
view process at this center, and this is likely the case at
other institutions and in other countries as well.
Taking a closer look at the first criteria, whether studies
used the term “pilot” or “feasibility” in the title of the in-
formed consent documents, we expected nearly 100% in-
clusion of this item, as the title of the study is to be
identical to the title of the informed consent documents,
according to the HiREB template for informed consent
forms [21]. It is unclear why many researchers are not in-
cluding the terms “pilot” or “feasibility” in the informed
consent documents, when they are included in the title of
the study. Perhaps researchers fear that recruitment or re-
tention rates would drop if participants knew the project
was a feasibility study, although there is no evidence to sup-
port the notion that recruitment/retention would decrease.
Nonetheless, more than a quarter of PAFS lacked the terms
“pilot” or “feasibility” in the title of the informed consent
documents, and thus researchers and REBs should be made
aware of this issue and cognisant of addressing it when de-
signing and reviewing informed consent documents.
Most research ethics guidelines state that language used
in informed consent forms should be in lay terms [11–16].
The terms “pilot study” and “feasibility study” are tech-
nical research terms that lay audiences should not be ex-
pected to understand, and yet only 12% of final informed
consent documents contained some definition or explan-
ation of what a pilot or feasibility study is. This number is
likely to be similarly low across other REBs as well. The
use of inappropriately complex language in consent docu-
ments is not limited to PAFS. O’Sullivan et al. evaluated
the reading difficulty of consent documents for various
studies and found that 91.6% of studies had ‘Fairly Diffi-
cult’ (40.3%) or ‘Difficult’ readability levels [22]. Although
the issue of readability is not unique to PAFS, defining
pilot or feasibility studies in their consent documents is
important for transparency and needs to be addressed by
REBs, researchers, and research ethics guidelines.
The TCPS2 was updated in 2018 to address informed
consent in pilot studies, stating that researchers have an
ethical responsibility to communicate the purpose and na-
ture of pilot studies to participants when seeking consent
[16]. However, our results indicate that most PAFS studies
failed to describe their feasibility objectives, implicating
that researchers and REBs are not providing adequate
transparency to participants in the informed consent
process of PAFS. Various research ethics guidelines state
that researchers ought to explain research procedures and
methods via the informed consent process, yet they do
not comment on how this applies to pilot studies [11–15].
It is possible that researchers and REBs are unaware of
how to ensure transparency in the informed consent
process, as it pertains to pilot studies. Research ethics
guidelines should address this issue by specifically ad-
dressing informed consent in pilot studies with clear de-
scriptions on what items should be communicated in the
informed consent documents. Moreover, training for re-
searchers and REBs should include guidance on informed
consent in pilot studies, and resources, checklists, and
templates should be developed and used in the design and
review of informed consent documents for pilot studies.
Left unaddressed, this issue of inadequate transparency
of informed consent in pilot studies has severe ethical
implications. If participants are left unaware of the pur-
pose of the studies they volunteer in, their rights can be
violated, the researchers’ credibility damaged, and trust
between participants and researchers broken. If partici-
pants learn they were misinformed during the informed
consent process they could feel betrayed; question the
integrity of researchers; decide not to participate in fu-
ture studies; question the integrity of research and evi-
denced based medicine; and even take legal action
against researchers, research sponsors, or research ethics
committees. This is especially concerning in the “post-
truth society” described by Iyengar and Massey [23], in
which scientists regularly encounter targeted media and
social media campaigns of fake news, misinformation,
and disinformation. Thus, it is imperative that the issue
of informed consent in PAFS is addressed urgently.
Study characteristics associated with transparency
Our study also aimed to determine methodological char-
acteristics associated with reporting or inclusion of the
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five criteria for transparency in informed consent docu-
ments. Due to the few number of studies including each
criteria for transparency, we were only able to perform
the binary logistic regression for studies that incorpo-
rated the terms “pilot” or “feasibility” in their title and
stated the primary objectives of the study were to assess
feasibility in the informed consent documents.
Studies that collected qualitative data were signifi-
cantly less likely to included “pilot” or “feasibility” in the
title of the informed consent documents, compared to
studies that collected both qualitative and quantitative
data. It is unclear as to why this correlation exists and
what impact it has, if any, on the design or development
of pilot studies and informed consent documents.
Our regression analysis showed that “feasibility”
studies were significantly more likely to state intent
to assess feasibility in their consent documents than
“pilot” studies. This could be a reflection of how
REBs focus their attention and suggested revisions.
Perhaps the term “feasibility study” is more closely
associated with assessment of feasibility compared to
the term “pilot study,” and thus it leads to more
suggested revisions to state the feasibility objectives
in the informed consent documents.
We also found that studies that stated the progression
criteria for the study to lead to a larger study in their pro-
tocols were more likely to state intent to assess feasibility
in their informed consent documents, compared to stud-
ies that did not state these criteria. This suggests that well
planned PAFS tend to be more transparent in their in-
formed consent practices, by stating their objectives are to
assess feasibility in their informed consent documents.
An interesting trend, although not statistically signifi-
cant, is that industry sponsored studies were less likely
to include “pilot” or “feasibility” in the title of their in-
formed consent documents. They were also less likely to
state that the primary objectives of the study were to as-
sess feasibility in the informed consent documents. Al-
though the finding is not statistically significant, it
suggests that industry-funded studies are less likely to
have transparent informed consent practices for PAFS.
Perhaps REBs should pay special attention when revising
informed consent documents of industry-funded PAFS.
With respect to temporality, the CONSORT extension
[20] for pilot studies was published in late 2016 and for
this reason we categorized the study dates to before
2017 and after or during 2017. We expected the trans-
parency of informed consent would increase after 2016,
due to the publication of recommendations in the CON-
SORT extension. However, we found the opposite trend
was true and that a fewer proportion of studies commu-
nicated their objectives were to assess feasibility in the
informed consent documents. It appears that the CON-
SORT extension has not yet improved communication
of the feasibility nature of the objectives of PAFS, again
highlighting the need for more resources and guidance
for researchers and REBs in addressing the lack of trans-
parency of informed consent in PAFS.
Limitations
It is important to address the limitations of this study, as
it only looked at one REB, in Canada. The results may
not be representative of all REBs; however, they are
likely similar to other REBs. Our analysis was also lim-
ited by the nature of the data. We were powered for our
primary objective but to address some secondary objec-
tives our data only allowed us to conduct multivariable
analysis for two of our five primary outcome measures
(whether the consent documents state “pilot” or “feasi-
bility” in their titles and whether they state intent to as-
sess feasibility). The other three outcomes did not have
enough events in the response variable for the number
of independent variables that we were fitting in the
model. Thus, these models would create over fitting and
be unstable. Nonetheless, this study provides empirical
evidence that informed consent in PAFS lacks transpar-
ency and that this issue needs to be addressed. Future
research should focus on quantifying this issue at other
centers and in other countries, identifying reasons for
poor informed consent practices, and developing ways to
improve informed consent in PAFS.
Conclusion
Informed consent in pilot studies submitted to the HiREB
is not transparent. This is a serious concern that can lead
to severe consequences and ethical implications. Although
steps have been taken, like the CONSORT extension and
TCPS2 update addressing pilot studies, this is insufficient.
More research ethics guidelines need to address informed
consent in PAFS and in more depth, that provides clear
and comprehensive instruction. Researchers and REBs
need to be made aware of issues of informed consent in
PAFS. Tools and resources should be developed on how
to appropriately address informed consent in PAFS to up-
hold the rights of participants.
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